PIONEER 3:経口セマグルチドはSGLT-2よりHbA1c低下、体重減少効果あり

１日１回経口セマグルチド oral semaglutide, a glucagon-like peptide 1 receptor agonist は、シタグリプチン(ジャヌビア）よりHbA1ｃ低下効果


7mg投与量にて　HbA1c  ベースラインから　-0.3% , 95%CI, -0.4% 〜 -0.1% P<0 .001="" p=""> 14mg投与量にて　-0.5%, 95% CI, -0.6 〜 -0.4% P<0 .001="" nbsp="" p="">

体重減少効果も良好 差 -1.6kg, 95% CI, -2.0 〜 -1.1kg、 -2.5 kg, 95% CI, -3.0 〜 -2.0kg P<0 .001="" p="">
Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea
The PIONEER 3 Randomized Clinical Trial
Julio Rosenstock, et al, ; for the PIONEER 3 Investigators
JAMA. Published online March 23, 2019. doi:10.1001/jama.2019.2942




<0 .001="" p=""><0 .001="" nbsp="" p=""><0 .001="" p="">
<0 .001="" p=""><0 .001="" nbsp="" p=""><0 .001="" p="">
<0 .001="" p=""><0 .001="" nbsp="" p=""><0 .001="" p="">
<0 .001="" p=""><0 .001="" nbsp="" p=""><0 .001="" p="">

---

Oral semaglutide demonstrates greater reductions in both HbA1c and body weight compared to Victoza® in Japanese people with type 2 diabetes
<0 .001="" p=""><0 .001="" nbsp="" p=""><0 .001="" p="">http://www.novonordisk.co.jp/content/Japan/AFFILIATE/www-novonordisk-co-jp/Extweb/news/2018/12/04/18-34.pdf